Imagion Biosystems Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	5.8yrs

Recent management updates

Recent updates

Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment

Feb 28

Here's Why We're Not Too Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Jan 06

CEO

Imagion Biosystems has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Proulx	Executive Chairman	7.4yrs	AU$574.54k	0.47% A$ 11.4k
David Ludvigson	Non Executive Director	7.2yrs	AU$49.32k	0.042% A$ 1.0k
Paul Grint	Member of Scientific Advisory Board	4.6yrs	no data	no data
Dianne Angus	Non-Executive Director	4yrs	AU$45.84k	0.025% A$ 598.2
John Hazle	Chairman of Scientific Advisory Board	5.8yrs	AU$17.80k	no data
Michael Harsh	Non-Executive Director	7.3yrs	AU$49.32k	0.020% A$ 481.0
Robert Ivkov	Member of Scientific Advisory Board	4.6yrs	no data	no data
Andrew Scott	Member of Scientific Advisory Board	4.6yrs	no data	no data
Jovanka Naumoska	Non Executive Director	7.4yrs	AU$45.84k	0.022% A$ 541.1
Mark Van Asten	Non Executive Director	7.4yrs	AU$45.84k	0.047% A$ 1.1k
Lisa Horvath	Member of Scientific Advisory Board	4.6yrs	no data	no data

5.8yrs

Average Tenure

65yo

Average Age

Experienced Board: IBX's board of directors are considered experienced (5.8 years average tenure).

Imagion Biosystems Management

Management criteria checks 1/4

Key information

Recent management updates

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Imagion Biosystems Limited Announces Departure of Isaac Bright as CEO

Imagion Biosystems Limited Approves Election of Isaac Bright as Director

Imagion Biosystems Limited Appoints Robert Proulx as Non-Executive Chairman

Imagion Biosystems Limited Announces CEO Changes

No independent directors

Recent updates

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.35 loss in FY 2022)

Imagion Biosystems Limited Announces Departure of Isaac Bright as CEO

Imagion Biosystems Limited Approves Election of Isaac Bright as Director

New major risk - Market cap size

First half 2023 earnings released: AU$0.007 loss per share (vs AU$0.005 loss in 1H 2022)

New major risk - Financial position

New minor risk - Financial data availability

Imagion Biosystems Limited Appoints Robert Proulx as Non-Executive Chairman

New minor risk - Share price stability

Imagion Biosystems Limited Announces CEO Changes

New major risk - Market cap size

Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Imagion Biosystems Limited Reports Positive Clinical Data At Breast Cancer Symposium

No independent directors

Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation

First half 2022 earnings released: AU$0.005 loss per share (vs AU$0.001 loss in 1H 2021)

No independent directors

Imagion Biosystems Limited, Annual General Meeting, May 25, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

We're Hopeful That Imagion Biosystems (ASX:IBX) Will Use Its Cash Wisely

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Imagion Biosystems Limited Announces First Patient Enrolled in the MagSense® HER2 Breast Cancer Phase I First-In-Human Study

We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

Imagion Biosystems Limited Receives CSIRO Grant for Prostate Cancer Project

Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment

Full year 2020 earnings released: AU$0.007 loss per share (vs AU$0.01 loss in FY 2019)

New 90-day high: AU$0.21

New 90-day high: AU$0.21

Here's Why We're Not Too Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Imagion Biosystems Limited Provides First-In-Human Study Update - Study Open for Enrolment

Imagion Biosystems Limited Announces Change of Company Secretary

Imagion Biosystems Limited announced that it expects to receive AUD 6 million in funding

Imagion Biosystems Limited Appoints Geoff Hollis as CFO

Imagion Biosystems Announces HREC Approval for Phase I Study

First half earnings released

CEO

Board Members

Average Tenure

Average Age